Alejandro Navarro

5.7k total citations · 2 hit papers
110 papers, 2.6k citations indexed

About

Alejandro Navarro is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alejandro Navarro has authored 110 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 49 papers in Pulmonary and Respiratory Medicine and 48 papers in Molecular Biology. Recurrent topics in Alejandro Navarro's work include Lung Cancer Research Studies (61 papers), Lung Cancer Treatments and Mutations (33 papers) and Cancer therapeutics and mechanisms (28 papers). Alejandro Navarro is often cited by papers focused on Lung Cancer Research Studies (61 papers), Lung Cancer Treatments and Mutations (33 papers) and Cancer therapeutics and mechanisms (28 papers). Alejandro Navarro collaborates with scholars based in Spain, United States and France. Alejandro Navarro's co-authors include Enriqueta Felip, S. Cedrés, Alex Martínez‐Martí, Pablo Martínez, Melissa L. Johnson, Todd M. Bauer, Antonello Abbattista, Justin F. Gainor, Alice T. Shaw and Benjamin Besse and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Alejandro Navarro

104 papers receiving 2.6k citations

Hit Papers

Pembrolizumab or Placebo Plus Etoposide and Platinum as F... 2017 2026 2020 2023 2020 2017 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
    2020 491 citations Charles M. Rudin, Mark M. Awad et al. profile →
  2. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
    2017 487 citations Alice T. Shaw, Enriqueta Felip et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alejandro Navarro Spain 19 2.0k 1.3k 669 613 305 110 2.6k
Alexander Luft Russia 16 2.0k 1.0× 1.0k 0.8× 398 0.6× 560 0.9× 163 0.5× 35 2.3k
William J. Geese United States 20 2.5k 1.2× 1.4k 1.1× 481 0.7× 298 0.5× 455 1.5× 43 3.0k
Mehmet Altan United States 24 2.1k 1.0× 885 0.7× 364 0.5× 376 0.6× 200 0.7× 121 2.5k
Akin Atmaca Germany 24 2.2k 1.1× 1.4k 1.1× 845 1.3× 580 0.9× 304 1.0× 61 3.3k
Motoko Tachihara Japan 21 1.1k 0.6× 1.2k 0.9× 443 0.7× 288 0.5× 249 0.8× 109 1.9k
Kai Li China 23 1.2k 0.6× 675 0.5× 477 0.7× 242 0.4× 341 1.1× 95 1.8k
Asim Amin United States 27 2.6k 1.3× 1.1k 0.8× 905 1.4× 346 0.6× 431 1.4× 73 3.4k
Saiama N. Waqar United States 29 1.7k 0.9× 1.9k 1.4× 654 1.0× 310 0.5× 551 1.8× 143 2.9k
Giulia Pasello Italy 23 1.1k 0.5× 1.1k 0.9× 510 0.8× 207 0.3× 349 1.1× 165 2.0k

Countries citing papers authored by Alejandro Navarro

Since Specialization
Citations

This map shows the geographic impact of Alejandro Navarro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro Navarro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro Navarro more than expected).

Fields of papers citing papers by Alejandro Navarro

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandro Navarro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro Navarro. The network helps show where Alejandro Navarro may publish in the future.

Co-authorship network of co-authors of Alejandro Navarro

This figure shows the co-authorship network connecting the top 25 collaborators of Alejandro Navarro. A scholar is included among the top collaborators of Alejandro Navarro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejandro Navarro. Alejandro Navarro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bedoya, C. Fernandez, D. Eliseev, D. Francia Ferrero, et al.. (2025). OBDT-theta, a multi-channel TDC and readout board for the CMS muon drift tubes in HL-LHC. 3.
2.
Cheng, Ying, David R. Spigel, Jian Fang, et al.. (2024). MA17.04 Patient-Reported Outcomes (PROs) With Consolidation Durvalumab Versus Placebo Following cCRT in Limited-Stage SCLC: ADRIATIC. Journal of Thoracic Oncology. 19(10). S124–S125. 1 indexed citations
3.
Rodríguez‐Abreu, Delvys, Byoung Chul Cho, Tibor Csőszi, et al.. (2024). Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC). Cancer Research. 84(7_Supplement). CT253–CT253. 2 indexed citations
4.
Cheng, Ying, Yu-Jung Kim, Alejandro Navarro, et al.. (2024). OA04.03 Ifinatamab Deruxtecan (I-DXd) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Interim Analysis of Ideate-lung01. Journal of Thoracic Oncology. 19(10). S15–S16. 14 indexed citations
5.
Cedrés, S., Patricia Iranzo, Ana Callejo, et al.. (2023). Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy. Cancers. 15(24). 5787–5787. 4 indexed citations
6.
Carbonell, Caterina, Joan Frigola, Núria Pardo, et al.. (2023). Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. Molecular Oncology. 17(5). 779–791. 4 indexed citations
7.
Ponce, Santiago, S. Cedrés, Charles Ricordel, et al.. (2023). ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment. Journal for ImmunoTherapy of Cancer. 11(9). e007552–e007552. 16 indexed citations
8.
Spigel, David R., Luis Paz‐Ares, Yuanbin Chen, et al.. (2021). MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity. Journal of Thoracic Oncology. 16(1). S32–S32. 2 indexed citations
9.
Ahn, M-J., Dariusz M. Kowalski, Byoung Chul Cho, et al.. (2021). 116TiP KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti–PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC). Annals of Oncology. 32. S1425–S1426. 1 indexed citations
10.
Cedrés, S., Santiago Ponce-Aix, Patricia Iranzo, et al.. (2020). Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. Clinical & Translational Oncology. 22(8). 1390–1398. 8 indexed citations
11.
Kim, Hye Ryun, Mark M. Awad, Alejandro Navarro, et al.. (2020). 1782MO Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC. Annals of Oncology. 31. S1033–S1034. 4 indexed citations
12.
Ponce, Santiago, Karl Brendel, David R. Spigel, et al.. (2020). 1793P RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC). Annals of Oncology. 31. S1038–S1039. 1 indexed citations
13.
Gonzalez, N. Saoudi, Patricia Iranzo, Ana Callejo, et al.. (2020). 1798P Carboplatin-paclitaxel (CP) chemotheraphy as salvage treatment for small cell lung cancer (SCLC): A real-world evidence analysis. Annals of Oncology. 31. S1041–S1041. 1 indexed citations
14.
15.
Bauer, Todd M., Alice T. Shaw, Melissa L. Johnson, et al.. (2018). MA08.05 Brain Penetration of Lorlatinib and Cumulative Incidence Rates for CNS and Non CNS Progression from a Phase 1/2 Study. Journal of Thoracic Oncology. 13(10). S382–S383. 4 indexed citations
16.
Mezquita, Laura, Santiago Ponce Aix, Édouard Auclin, et al.. (2018). P3.12-11 Association of the Lung Immune Prognostic Index (LIPI) with Outcomes for Immune Checkpoint Inhibitors in Diffuse SCLC Patients. Journal of Thoracic Oncology. 13(10). S973–S974. 1 indexed citations
17.
Prat, Aleix, Alejandro Navarro, Laia Paré, et al.. (2017). Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. Cancer Research. 77(13). 3540–3550. 277 indexed citations
18.
Remón, Jordi, Alex Martínez‐Martí, Enric Carcereny, et al.. (2017). Major pathological response after preoperative chemotherapy as a surrogate marker of survival in early-stage non-small cell lung cancer: cohort of NATCH phase III trial. Annals of Oncology. 28. v454–v454. 7 indexed citations
19.
Thomas, Michael, Santiago Ponce-Aix, Alejandro Navarro, et al.. (2017). Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod. Annals of Oncology. 28. v539–v539. 5 indexed citations
20.
Zurlo, Alfredo, Santiago Ponce Aix, Jorge Riera Knorrenschild, et al.. (2015). Immunomodulatory switch maintenance therapy to improve overall survival in small cell lung cancer (SCLC): The randomized IMPULSE study. Annals of Oncology. 26. viii5–viii5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alexander Luft Breakdown of academic impact, for papers by William J. Geese Breakdown of academic impact, for papers by Mehmet Altan Breakdown of academic impact, for papers by Akin Atmaca Breakdown of academic impact, for papers by Motoko Tachihara Breakdown of academic impact, for papers by Kai Li Breakdown of academic impact, for papers by Asim Amin Breakdown of academic impact, for papers by Saiama N. Waqar Breakdown of academic impact, for papers by Giulia Pasello
Rankless by CCL
2026